[go: up one dir, main page]

AU2002321884A1 - A method for preparing fluticasone derivatives - Google Patents

A method for preparing fluticasone derivatives

Info

Publication number
AU2002321884A1
AU2002321884A1 AU2002321884A AU2002321884A AU2002321884A1 AU 2002321884 A1 AU2002321884 A1 AU 2002321884A1 AU 2002321884 A AU2002321884 A AU 2002321884A AU 2002321884 A AU2002321884 A AU 2002321884A AU 2002321884 A1 AU2002321884 A1 AU 2002321884A1
Authority
AU
Australia
Prior art keywords
derivatives
preparing fluticasone
preparing
fluticasone derivatives
fluticasone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002321884A
Inventor
John Joseph Partridge
Dwight Sherod Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2002321884A1 publication Critical patent/AU2002321884A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Steroid Compounds (AREA)
AU2002321884A 2001-08-03 2002-08-01 A method for preparing fluticasone derivatives Abandoned AU2002321884A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36734101P 2001-08-03 2001-08-03
US60/367,341 2001-08-03
PCT/US2002/024586 WO2003013427A2 (en) 2001-08-03 2002-08-01 A method for preparing fluticasone derivatives

Publications (1)

Publication Number Publication Date
AU2002321884A1 true AU2002321884A1 (en) 2003-02-24

Family

ID=23446772

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002321884A Abandoned AU2002321884A1 (en) 2001-08-03 2002-08-01 A method for preparing fluticasone derivatives

Country Status (2)

Country Link
AU (1) AU2002321884A1 (en)
WO (1) WO2003013427A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
PT2348032E (en) 2000-08-05 2015-10-14 Glaxo Group Ltd 6.alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CA2445839A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
AR036872A1 (en) 2001-08-13 2004-10-13 Du Pont ANTRANILAMIDE COMPOSITE, COMPOSITION THAT INCLUDES IT AND METHOD FOR CONTROLLING AN INVERTEBRATE PEST
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP2013536835A (en) 2010-09-01 2013-09-26 カディラ・ヘルスケア・リミテッド Method for preparing propionic acid / fluticasone furoate
CN106279341A (en) * 2015-05-11 2017-01-04 正大天晴药业集团股份有限公司 A kind of preparation method of fluticasone furoate
CN108659090A (en) * 2017-03-31 2018-10-16 天津药业研究院有限公司 A kind of preparation method of 17 β-thiocarboxylic acids chloromethane esters steroidal compounds
WO2021161263A1 (en) * 2020-02-13 2021-08-19 Abbvie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989686A (en) * 1972-06-15 1976-11-02 Glaxo Laboratories Limited Anaesthetic steroids of the androstane series and process for preparing same
US4093721A (en) * 1974-08-30 1978-06-06 Glaxo Laboratories Limited Pharmaceutical compositions of 6α,9α-difluoro-androst-4-ene-17β-carboxylates and derivatives thereof
ZA81976B (en) * 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
IL109656A (en) * 1994-05-15 1998-02-22 Chemagis Ltd Process for the manufacture of androstane - 17 - carbothioates and androstane - 17 - carbothioates prepared thereby
US20020133032A1 (en) * 2000-02-25 2002-09-19 Jufang Barkalow Method for the preparation of fluticasone and related 17beta-carbothioic esters using a novel carbothioic acid synthesis and novel purification methods

Also Published As

Publication number Publication date
WO2003013427A3 (en) 2003-10-16
WO2003013427A2 (en) 2003-02-20

Similar Documents

Publication Publication Date Title
AU2002300036A1 (en) Method for creating a workflow
AU2002357049A1 (en) Methods for preparing 0-desmethylvenlafaxine
AU2002321884A1 (en) A method for preparing fluticasone derivatives
AU2002340249A1 (en) Method for making a refastenable undergarment
AU2002367375A1 (en) Method for automatically defining a part model
AU2003255554A1 (en) A method for bricklaying
AU2141400A (en) Method for a robot
EP1298117A3 (en) Method for preparing bromofluorenes
AU3734301A (en) Method for producing 2-chloro-benzimidazole derivatives
AU2003223855A1 (en) Method for operating a call-centre
AU2003298519A1 (en) Methods for preparing a solid-fibrin web
AU2001246636A1 (en) Method for preparing 9-deoxo-8a-aza-(8a-alkyl)-8a-homoerythromycin A derivatives from 9-deoxo-9(Z)-hydroxyiminoerythromycin A
AU2002310874A1 (en) Single-step method for producing toluene derivatives
AU2003222342A1 (en) Method for preparing $g(v)-bromoalkylcarboxylic compounds
AU2002229689A1 (en) Method for preparing latex
AU2002365852A1 (en) Processes for preparing %a-d-ribofuranose derivatives
AU2002364618A1 (en) Method for preparing an aminobenzofuran compound
AU2002241271A1 (en) Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate
AU2002317921A1 (en) Method for preparing oestrogen derivatives
AU7015900A (en) Method for monohalogenating aminoaromatic derivatives
AU2002338115A1 (en) Method for preparing cobalt-protein complex
AU2002361475A1 (en) A method for packing electrochemically-deposited elements
AU2002346864A1 (en) Method for preparing alkoxycarbonylamino-triazines
AU2002336131A1 (en) Method for preparing 4-methylamino-4-phenylpiperidine
AU2002333993A1 (en) Method for preparing 4-amino-4-phenylpiperidines

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase